Razek Georges Coussa
Retina Specialist · Oklahoma City, OKNPI 1700362522
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,479 of the $10,373 with a category attached, or 72.1%. 10 manufacturers reported payments, led by Alcon at 45.4% of the total. Reporting peaked in 2023 at $5,003 and has fallen 50.8% since, to $2,460 in 2025.
Across 28 payments — averaging $370.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- Dutch Ophthalmic, USA$3K
- Neurotech Pharmaceuticals, Inc.$2K
- Astellas Pharma US Inc$416
- Regeneron Healthcare Solutions, Inc.$125
- Genentech USA, Inc.$103
- plus $158 from 4 others
What the payments were for
- Consulting fees$7,47972%
- Travel & lodging$1,44614%
- Food & beverage$1,37813%
- Entertainment$711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $4,714 |
| Dutch Ophthalmic, USA | 7 | $2,779 |
| Neurotech Pharmaceuticals, Inc. | 1 | $2,079 |
| Astellas Pharma US Inc | 6 | $416 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Genentech USA, Inc. | 3 | $103 |
| Optos, Inc. | 1 | $71 |
| ANI Pharmaceuticals, Inc. | 1 | $49 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FINESSE SHARKSKIN$4,596
- EVA, combined machine$2,745
- TISSUEBLUE$2,745
- Izervay$258
- EYLEA HD$125
How this compares
Too few retina specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 205 | $7,375 |
| MoxifloxacinMoxifloxacin Hcl | 20 | $763 |
| Atropine Sulfate | 21 | $697 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $697 |
| Brimonidine Tartrate | 61 | $545 |
| Latanoprost | 23 | $472 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Oklahoma City
- Vinay ShahOklahoma City$95K
- Jordan JohnsonOklahoma City$4K
- Sumit NandaOklahoma City$3K
- Ronald KingsleyOklahoma City$1K
- Stanley ParkOklahoma City$964
- Robert LeonardOklahoma City$731
- Reagan BradfordOklahoma City$566
- Miguel Cruz PimentelOklahoma City$86
- Sandeep ShahEdmond$24K
- Brian PhelpsEdmond$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.